DIFFERENTIAL EXPRESSION PATTERN OF AIP, UCKL1, AND PKN1 GENES IN PROSTATE CANCER PATIENTS.

Q3 Medicine

Experimental oncology Pub Date : 2022-05-01 DOI:10.32471/exp-oncology.2312-8852.vol-44-no-1.17380

L. Kovalevska, T. Zadvornyj, N. Lukianova, E. Kashuba

{"title":"DIFFERENTIAL EXPRESSION PATTERN OF AIP, UCKL1, AND PKN1 GENES IN PROSTATE CANCER PATIENTS.","authors":"L. Kovalevska, T. Zadvornyj, N. Lukianova, E. Kashuba","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-1.17380","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nThe evolution of research on the therapy of prostate cancer (PC) depends on a study of molecules that are involved in the progression of this disease. Nevertheless, there is a need for additional biomarkers that would help to refine the molecular profile of PC and propose the personalized therapeutic approach.\n\n\nAIM\nTo study differential expression patterns of the AIP, UCKL1, and PKN1 genes in blood sera and tumor tissue of patients with PC with different Gleason scores.\n\n\nMATERIALS AND METHODS\nThe total extracellular RNA was isolated from blood sera of 44 PC patients and 4 healthy donors. cDNAs were synthesized and quantitative polymerase chain reaction (qPCR) was performed. Immunohistochemical study of the UCKL, AIP and PKN1 proteins was performed on deparaffinized sections of tumors. The study was supplemented by a bioinformatic analysis of the publicly available databases.\n\n\nRESULTS\nThe UCKL1, AIP, PKN1 genes were overexpressed at the mRNA level in blood sera of PC patients, compared to healthy donors. Extracellular mRNA levels of AIP and UCKL-1 were 100-1000-fold increased in all PC samples compared to the healthy donors but without significant inequality between the groups of PC cases differing by the Gleason score. The highest levels were detected in the samples from PC patients with the Gleason score > 9. The PKN1 expression was higher in PC patients compared with healthy donors but without significant difference between the groups.\n\n\nCONCLUSIONS\nFrom the three chosen genes, AIP and UCKL1 showed similar pattern of expression assessed either by extracellular mRNA levels in patient sera or the protein in PC tissues. AIP was up to 1000-fold increased in all PC samples, compared to the healthy donors, with the highest levels in PC cases with Gleason score > 9. Expression levels of the AIP and UCKL1 genes in the PC patient sera may be used as an additional criterion for prognosis of tumor progression.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 1 1","pages":"47-51"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-1.17380","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

BACKGROUND The evolution of research on the therapy of prostate cancer (PC) depends on a study of molecules that are involved in the progression of this disease. Nevertheless, there is a need for additional biomarkers that would help to refine the molecular profile of PC and propose the personalized therapeutic approach. AIM To study differential expression patterns of the AIP, UCKL1, and PKN1 genes in blood sera and tumor tissue of patients with PC with different Gleason scores. MATERIALS AND METHODS The total extracellular RNA was isolated from blood sera of 44 PC patients and 4 healthy donors. cDNAs were synthesized and quantitative polymerase chain reaction (qPCR) was performed. Immunohistochemical study of the UCKL, AIP and PKN1 proteins was performed on deparaffinized sections of tumors. The study was supplemented by a bioinformatic analysis of the publicly available databases. RESULTS The UCKL1, AIP, PKN1 genes were overexpressed at the mRNA level in blood sera of PC patients, compared to healthy donors. Extracellular mRNA levels of AIP and UCKL-1 were 100-1000-fold increased in all PC samples compared to the healthy donors but without significant inequality between the groups of PC cases differing by the Gleason score. The highest levels were detected in the samples from PC patients with the Gleason score > 9. The PKN1 expression was higher in PC patients compared with healthy donors but without significant difference between the groups. CONCLUSIONS From the three chosen genes, AIP and UCKL1 showed similar pattern of expression assessed either by extracellular mRNA levels in patient sera or the protein in PC tissues. AIP was up to 1000-fold increased in all PC samples, compared to the healthy donors, with the highest levels in PC cases with Gleason score > 9. Expression levels of the AIP and UCKL1 genes in the PC patient sera may be used as an additional criterion for prognosis of tumor progression.

查看原文本刊更多论文

前列腺癌患者AIP、UCKL1和PKN1基因的差异表达模式。

背景癌症（PC）治疗研究的进展取决于对参与该疾病进展的分子的研究。然而，需要额外的生物标志物来帮助完善PC的分子图谱，并提出个性化的治疗方法。目的研究不同Gleason评分的PC患者血清和肿瘤组织中AIP、UCKL1和PKN1基因的差异表达模式。材料和方法从44例PC患者和4名健康献血员的血清中分离出细胞外总RNA。合成cDNA并进行定量聚合酶链反应（qPCR）。在肿瘤的去亲和切片上进行了UCKL、AIP和PKN1蛋白的免疫组织化学研究。这项研究得到了对公开数据库的生物信息学分析的补充。结果与健康献血者相比，PC患者血清中UCKL1、AIP、PKN1基因在mRNA水平上过表达。与健康供体相比，所有PC样本中AIP和UCKL-1的细胞外mRNA水平增加了100-1000倍，但Gleason评分不同的PC病例组之间没有显著差异。在Gleason评分>9的PC患者的样本中检测到最高水平。与健康供体相比，PC患者的PKN1表达更高，但两组之间没有显著差异。结论从所选的三个基因中，无论是从患者血清中的细胞外mRNA水平还是PC组织中的蛋白质水平来看，AIP和UCKL1都显示出相似的表达模式。与健康供体相比，所有PC样本的AIP增加了1000倍，其中Gleason评分>9的PC病例的AIP水平最高。PC患者血清中AIP和UCKL1基因的表达水平可作为肿瘤进展预后的额外标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.